EW Q3 2023 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q3 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.2B-5.7% YoY

Gross Profit

$971M78.1% margin

Operating Income

$347M27.9% margin

Net Income

$385M31.0% margin

EPS (Diluted)

$0.63

QoQ Revenue Growth

-4.0%

Cash Flow

Operating Cash Flow

$412M

Free Cash Flow

$356M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$9.4B

Total Liabilities

$2.6B

Stockholders' Equity

$6.7B

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.2B	$1.3B	-5.7%
Gross Profit	$971M	$1.0B	-6.4%
Operating Income	$347M	$427M	-18.9%
Net Income	$385M	$344M	+12.1%

Revenue Segments

Transcatheter Heart Valves

$961M65%

Surgical Heart Valve Therapy

$247M17%

Critical Care

$221M15%

Transcatheter Mitral And Tricuspid Therapies

$52M4%

Geographic Segments

UNITED STATES

$870M59%

Europe

$322M22%

Rest of World

$180M12%

JAPAN

$108M7%